• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

mBio . Viral Mimicry of Interleukin-17A by SARS-CoV-2 ORF8

tetano

Editor, Senior Moderator
mBio


. 2022 Mar 28;e0040222.
doi: 10.1128/mbio.00402-22. Online ahead of print.
Viral Mimicry of Interleukin-17A by SARS-CoV-2 ORF8


Xin Wu[SUP] 1 [/SUP], Tian Xia[SUP] 1 [/SUP], Woo-Jin Shin[SUP] 1 2 [/SUP], Kwang-Min Yu[SUP] 3 [/SUP], Wooram Jung[SUP] 1 [/SUP], Alexandra Herrmann[SUP] 4 [/SUP], Suan-Sin Foo[SUP] 1 [/SUP], Weiqiang Chen[SUP] 1 [/SUP], Pengfei Zhang[SUP] 1 [/SUP], Jong-Soo Lee[SUP] 5 [/SUP], Haryoung Poo[SUP] 6 [/SUP], Suzy A A Comhair[SUP] 7 [/SUP], Lara Jehi[SUP] 8 [/SUP], Young Ki Choi[SUP] 3 [/SUP], Armin Ensser[SUP] 4 [/SUP], Jae U Jung[SUP] 1 [/SUP]



Affiliations

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection triggers cytokine-mediated inflammation, leading to a myriad of clinical presentations in COVID-19. The SARS-CoV-2 open reading frame 8 (ORF8) is a secreted and rapidly evolving glycoprotein. Patients infected with SARS-CoV-2 variants with ORF8 deleted are associated with mild disease outcomes, but the molecular mechanism behind this is unknown. Here, we report that SARS-CoV-2 ORF8 is a viral cytokine that is similar to but distinct from interleukin 17A (IL-17A) as it induces stronger and broader human IL-17 receptor (hIL-17R) signaling than IL-17A. ORF8 primarily targeted blood monocytes and induced the heterodimerization of hIL-17RA and hIL-17RC, triggering a robust inflammatory response. Transcriptome analysis revealed that besides its activation of the hIL-17R pathway, ORF8 upregulated gene expression for fibrosis signaling and coagulation dysregulation. A naturally occurring ORF8 L84S variant that was highly associated with mild COVID-19 showed reduced hIL-17RA binding and attenuated inflammatory responses. This study reveals how SARS-CoV-2 ORF8 by a viral mimicry of the IL-17 cytokine contributes to COVID-19 severe inflammation. IMPORTANCE Patients infected with SARS-CoV-2 variants lacking open reading frame 8 (ORF8) have been associated with milder infection and disease outcome, but the molecular mechanism behind how this viral accessory protein mediates disease pathogenesis is not yet known. In our study, we revealed that secreted ORF8 protein mimics host IL-17 to activate IL-17 receptors A and C (IL-17RA/C) and induces a significantly stronger inflammatory response than host IL-17A, providing molecular insights into the role of ORF8 in COVID-19 pathogenesis and serving as a potential therapeutic target.

Keywords: COVID-19; inflammation; viral IL-17.
 
Back
Top Bottom